S229-119

Introduced

To amend title XI of the Social Security Act to require that direct-to-consumer advertisements for prescription drugs and biological products include an appropriate disclosure of pricing information.

119th Congress Introduced Jan 23, 2025

Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.

Summary

What This Bill Does

This bill, To amend title XI of the Social Security Act to require that direct-to-consumer advertisements for prescription drugs and biological products include an appropriate disclosure of pricing information., changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Government Operations, Foreign Policy.

Who Benefits and How

health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.

Who Bears the Burden and How

federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.

Key Provisions

  • Section S1: 1. Short title This Act may be cited as the Drug-price Transparency for Consumers Act of 2025 or the DTC Act of 2025.
  • Section id59900bd27fbc429393961f0c0495bd1e: 2. Findings; sense of the Senate Congress finds the following: Direct-to-consumer advertising of prescription pharmaceuticals is legally permitted in only 2...
  • Section idd7e630fe6de942a1affa1012ef3b6864: 3. Requirement that direct-to-consumer advertisements for prescription drugs and biological products include an appropriate disclosure of pricing information...
  • Section idCC15F363943C4471AD25977E9FB4334F: 1150D. Requirement that direct-to-consumer advertisements for prescription drugs and biologicals include an appropriate disclosure of pricing information...

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

This bill, To amend title XI of the Social Security Act to require that direct-to-consumer advertisements for prescription drugs and biological products include an appropriate disclosure of pricing information., changes federal law or congressional policy affecting health care providers and patients.

Key Policy Areas

Healthcare, Government Operations, Foreign Policy

Primary Purpose

This bill, To amend title XI of the Social Security Act to require that direct-to-consumer advertisements for prescription drugs and biological products include an appropriate disclosure of pricing information., changes federal law or congressional policy affecting health care providers and patients.

Policy Domains

Healthcare Government Operations Foreign Policy

Whole bill

Identified Gains
  • health care providers and patients
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: is
health care providers and patients: ,
Identified Costs
  • federal implementing agencies
  • health care providers and patients
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: is
federal implementing agencies: ,
health care providers and patients: ,

Legislative Progress

Introduced
Introduced Committee Passed
Jan 23, 2025

Mr. Durbin (for himself, Mr. Grassley, Mr. King, Ms. Ernst, …

Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Healthcare Government Operations Foreign Policy
Actor Mappings
"secretary_of_health_and_human_services"
→ Secretary of Health and Human Services

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology